Skip to Content
Merck
CN
  • Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.

Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.

PloS one (2014-05-23)
Preethi S Nair, Shrimati D Shetty, S Chandrakala, Kanjaksha Ghosh
ABSTRACT

Despite increased awareness and diagnostic facilities, 70-80% of the haemophilia A (HA) patients still remain undiagnosed in India. Very little data is available on prevalent mutations in HA from this country. We report fifty mutations in seventy one Indian HA patients, of which twenty were novel. Ten novel missense mutations [p.Leu11Pro (p.Leu-8Pro), p.Tyr155Ser (p.Tyr136Ser), p.Ile405Thr (p.Ile386Thr), p.Gly582Val (p.Gly563Val) p.Thr696Ile (p.Thr677Ile), p.Tyr737Cys (p.Tyr718Cys), p.Pro1999Arg (p.Pro1980Arg), p.Ser2082Thr (p.Ser2063Thr), p.Leu2197Trp (p.Leu2178Trp), p.Asp2317Glu (p.Asp2298Glu)] two nonsense [p.Lys396* (p.Lys377*), p.Ser2205* (p.Ser2186*)], one insertion [p.Glu1268_Asp1269ins (p.Glu1249_Asp1250)] and seven deletions [p.Leu882del (p.Leu863del), p.Met701del (p.Met682del), p.Leu1223del (p.Leu1204del), p.Trp1961_Tyr1962del (p.Trp1942_Tyr1943del) p.Glu1988del (p.Glu1969del), p.His1841del (p.His1822del), p.Ser2205del (p.Ser2186del)] were identified. Double mutations (p.Asp2317Glu; p.Thr696Ile) were observed in a moderate HA case. Mutations [p. Arg612Cys (p.Arg593Cys), p.Arg2326Gln (p.Arg2307Gln)] known to be predisposing to inhibitors to factor VIII (FVIII) were identified in two patients. 4.6% of the cases were found to be cross reacting material positive (CRM+ve). A wide heterogeneity in the nature of mutations was seen in the present study which has been successfully used for carrier detection and antenatal diagnosis in 10 families affected with severe to moderate HA.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acrylamide, ≥99.9%
Sigma-Aldrich
Acrylamide, ≥98.0%
Supelco
Ethylene glycol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ethylene glycol, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
Formamide, BioUltra, Molecular Biology, ≥99.5% (T)
Sigma-Aldrich
Acrylamide, purum, ≥98.0% (GC)
Sigma-Aldrich
Ethidium bromide solution, suitable for fluorescence, ~1% in H2O
Sigma-Aldrich
Acrylamide, for Northern and Southern blotting, powder blend
Sigma-Aldrich
Formamide, ACS reagent, ≥99.5%
Sigma-Aldrich
Acrylamide, suitable for electrophoresis, ≥99% (HPLC), powder
Sigma-Aldrich
Acrylamide, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Ethidium bromide solution, BioReagent, Molecular Biology, 10 mg/mL in H2O
Sigma-Aldrich
Ethidium bromide solution, BioReagent, Molecular Biology, 500 μg/mL in H2O
Sigma-Aldrich
Acrylamide, Molecular Biology, ≥99% (HPLC)
Sigma-Aldrich
Formamide, ≥99.5% (GC), BioReagent, Molecular Biology
USP
Ethylene glycol, United States Pharmacopeia (USP) Reference Standard
Supelco
Ethylene glycol, analytical standard
Supelco
Acrylamide, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Acrylamide, analytical standard
Sigma-Aldrich
Ethylene glycol, anhydrous, 99.8%
Supelco
Ethylene glycol solution, suitable for NMR (reference standard), 80% in DMSO-d6 (99.9 atom % D), NMR tube size 5 mm × 8 in.
Sigma-Aldrich
Ethylene glycol, ReagentPlus®, ≥99%
Sigma-Aldrich
Ethylene glycol, spectrophotometric grade, ≥99%
Sigma-Aldrich
Formamide, spectrophotometric grade, ≥99%
Sigma-Aldrich
Formamide, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Formamide, Vetec, reagent grade, 98%
Sigma-Aldrich
Ethylene glycol, Vetec, reagent grade, 98%
Sigma-Aldrich
Piperazine, ReagentPlus®, 99%
Sigma-Aldrich
Acrylamide solution, 40%, suitable for electrophoresis, sterile-filtered
Sigma-Aldrich
Ethidium bromide, ~95% (HPLC)